Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1

Status

Terminated 2Recruiting 2Completed 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Neoplasm Metastasis 1Hematologic Neoplasms 1Agnosia 1

Interventions

pembrolizumab 111Carboplatin 45Nivolumab 41Paclitaxel 34Cyclophosphamide 32Cisplatin 32Gemcitabine 30atezolizumab 27venetoclax 25Specimen Handling 25Magnetic Resonance Spectroscopy 24Pemetrexed 23fludarabine 22Docetaxel 22Biopsy 22Radiotherapy 21Ipilimumab 21Bevacizumab 21Azacitidine 21Radiosurgery 18Dexamethasone 18durvalumab 17Fluorouracil 17Cetuximab 16fludarabine phosphate 14Trastuzumab 14tislelizumab 13Leucovorin 13Cytarabine 13olaparib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Oxycodone × 1 year × Clear all
NCT05597878 2026-06-01

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

Wake Forest University Health Sciences

Phase 2/3 Terminated
58 enrolled
Genitourinary

Agnosia, Prostatic Neoplasms

NCT03579446 2025-08-03

Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Terminated
43 enrolled
Other hematologic neoplasm

Neoplasm Metastasis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡